With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108258-54-4,Methyl 2,3-dichloroquinoxaline-6-carboxylate,as a common compound, the synthetic route is as follows.
Step C hydrazine monohydrate (0.26 ML) was added dropwise to a suspension of 2,3-dichloro-quinoxaline-6-carboxylic acid methyl ester (1.2 g) in methanol (10 ML) at -10 C. After three hrs. at this temperature, an additional portion of hydrazine monohydrate (0.26 ML) was added, and the resulting mixture was stirred at 0 C. for three hrs., and then for one hr. at 23 C. The suspension was filtered, and the solids were washed with MeOH. Flash column chromatography provided a residue that was recrystallized from MeOH to provide 3-chloro-2-hydrazino-quinoxaline-6-carboxylic acid methyl ester as a yellow solid. MS (M+H)+=253.2.
108258-54-4, The synthetic route of 108258-54-4 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Pfizer Inc.; US2004/192698; (2004); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider